cyprotex
the ADME Tox specialists
welcome to cyprotex

Investor News

February 17, 2003 - Board changes

Cyprotex plc announced today that Dr Colin Picton will become non-executive Chairman of the Company with immediate effect, following the resignation of Jeremy Scudamore. Colin is already familiar with Cyprotex's business, having served as a non-executive Director of the Company since February 2002.

Cyprotex also announces Dr Mark Egerton's intention to step down as Chief Executive Officer in order to pursue other business interests. Mark will continue to fulfil his executive responsibilities while the Board actively searches for a replacement.

Dr David Leahy, Chief Scientific Officer and Founder of Cyprotex plc, said:

"The Board is pleased to welcome Colin as non-executive Chairman and would like to thank Jeremy and Mark for their significant contribution to the Company and wish them every success in the future."

- Ends -

Cyprotex plc
John Nicholson, Chief Operating Officer

Tel: +44 (0) 1625 505 100

Bankside
Henry Harrison-Topham - henry.ht@bankside.com

Tel: +44 (0) 20 7444 4140

view all the latest news +
2013 archive +
2012 archive +
2011 archive +
2010 archive +
2009 archive +
2008 archive +
2007 archive +
2006 archive +
2005 archive +
2004 archive +
2003 archive +
2002 archive +
contact

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100

contact
careerscontactlegalprivacy
This website was last updated
on 22nd April 2014
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.